Article
Oncology
Najmeh Bozorgmehr, Isobel Okoye, Siavash Mashhouri, Julia Lu, Petya Koleva, John Walker, Shokrollah Elahi
Summary: This study revealed the immunosuppressive nature of CD71(+) erythroid cells and their association with response to PD-L1 therapy. The expansion of these cells was found to be related to anemia and poor immunotherapy outcomes. Additionally, EPO treatment was shown to promote the generation of these cells and attenuate the therapeutic effects of ICIs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Yanjun Wang, Shuo Yang, Li Wan, Wei Ling, Hao Chen, Jinghua Wang
Summary: The use of immune checkpoint inhibitors (ICIs) has shown effectiveness in treating various types of cancer and remains a major research focus. However, only a subset of patients experience improved survival rates due to drug resistance complexity. Further research is needed to identify predictive biomarkers that differentiate responders and non-responders. Combination therapies involving ICIs and other treatment modalities have potential in overcoming ICIs resistance, but more preclinical and clinical trials are necessary. Prompt recognition and intervention of immune-related adverse events are crucial for optimizing ICI use in clinical treatment. The current study aimed to review the mechanisms and applications of ICIs to provide a theoretical basis for clinicians.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Dong Shao, Yaping Chen, Hao Huang, Yingting Liu, Junjun Chen, Dawei Zhu, Xiao Zheng, Lujun Chen, Jingting Jiang
Summary: This study demonstrates that the combination therapy of LAG3 blockade and microwave ablation (MWA) is a unique treatment strategy for certain solid tumors, which can alter the tumor microenvironment and extend survival.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
G. Manson, P. Brice, C. Herbaux, M. G. Silva, K. Bouabdallah, B. Deau, J. Bouteloup, J. M. Schiano, E. Nicolas-Virelizier, M. Maerevoet, H. Ghesquieres, A. Stamatoullas, C. Antier, C. Carlo-Stella, M. de Charette, F. Poizeau, L. Dercle, Roch Houot
Summary: This study investigated the optimal duration of treatment and the risk of relapse after anti-PD1 therapy in patients with R/R HL. A machine learning algorithm was used to predict PFS, with age, time to best response, and response quality identified as important variables.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Oncology
Alexander F. Haddad, Jacob S. Young, Sabraj Gill, Manish K. Aghi
Summary: Immunotherapies, especially immune checkpoint blockade, have shown promise in treating cancer by unleashing the immune system against cancer cells. However, the efficacy varies across cancer types and some patients do not respond to these therapies. Understanding the underlying mechanisms of resistance is crucial for predicting response and tailoring personalized treatment paradigms.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Kyle Hansen, Sandeep Kumar, Kathryn Logronio, Sarah Whelan, Samir Qurashi, Hsin-Yuan Cheng, Andrew Drake, Margaret Tang, Patrick Wall, David Bernados, Ling Leung, Eran Ophir, Zoya Alteber, Gady Cojocaru, Moran Galperin, Masha Frenkel, Mark White, John Hunter, Spencer C. Liang, Maya F. Kotturi
Summary: TIGIT and its cognate ligand PVR are widely expressed in human cancers, and the antibody COM902 targeting TIGIT shows potential in enhancing anti-tumor immune responses both in-vitro and in-vivo, making it a promising candidate for the treatment of advanced malignancies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Lucile Pabst, Sebastien Lopes, Basil Bertrand, Quentin Creusot, Maria Kotovskaya, Erwan Pencreach, Michele Beau-Faller, Celine Mascaux
Summary: The therapeutic algorithm for lung cancer has been revolutionized by immune checkpoint inhibitors, but the response rate and adverse events remain a challenge. Predictive and prognostic biomarkers are needed to select patients who will respond to treatment. Currently, PD-L1 expression is the only validated biomarker, but its predictive value is imperfect. New molecular features, such as tumor mutational burden, have shown promise in predicting response to immunotherapy. This review summarizes the latest knowledge on predictive and prognostic biomarkers to advance precision immuno-oncology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Vladimir Laletin, Pierre-Louis Bernard, Cathy Costa da Silva, Geoffrey Guittard, Jacques A. Nunes
Summary: Immunotherapy strategies targeting T cells have been effective in treating cancer by blocking immune checkpoints. However, many patients do not respond to these treatments, so alternative approaches are needed. In addition to membrane-associated inhibitory molecules, intracellular immune checkpoints (iICPs) may also downregulate TCR signaling and inhibiting them shows promise for future cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Yongqing Liu, Pengbo Hu, Liang Xu, Xiuyuan Zhang, Zhou Li, Yiming Li, Hong Qiu
Summary: The landscape of gastric cancer treatment has changed due to the use of immune checkpoint inhibitors, but only a subset of patients have benefited significantly. The identification of effective biomarkers for immunotherapy is an important research topic. This review presents a summary of predictive biomarkers that have been recently studied in clinical research.
Article
Oncology
Omid Hamid, Jessica C. Hassel, Alexander N. Shoushtari, Friedegund Meier, Todd M. Bauer, April K. S. Salama, John M. Kirkwood, Paolo A. Ascierto, Paul C. Lorigan, Cornelia Mauch, Marlana Orloff, Thomas R. Jeffry Evans, Chris Holland, Ramakrishna Edukulla, Shaad E. Abedin, Mark R. Middleton
Summary: This study evaluated the safety and efficacy of Tebentafusp in combination with durvalumab and/or tremelimumab for metastatic cutaneous melanoma. The results showed that the combination therapy was safe and demonstrated some efficacy, suggesting potential therapeutic value for patients with advanced melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Zena Salih, Antonia Banyard, Joshua Tweedy, Elena Galvani, Philippa Middlehurst, Sarah Mills, John Weightman, Avinash Gupta, Paul C. Lorigan, Cong Zhou, Nathalie Dhomen, Sara Valpione, Richard Marais
Summary: This study found that immunotherapy can induce changes in the clonality and diversity of the peripheral T cell receptor repertoire in patients with melanoma. Age has an impact on treatment response, with different age groups showing different response patterns.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Shuguang Zuo, Min Wei, Bohao He, Anxian Chen, Shiqun Wang, Lingkai Kong, Yenan Zhang, Gang Meng, Tiancheng Xu, Jingyi Wu, Fuming Yang, Hailin Zhang, Shibing Wang, Ciliang Guo, Junhua Wu, Jie Dong, Jiwu Wei
Summary: The study demonstrates that VV-alpha-TIGIT exhibits effective anti-tumor efficacy in various tumor models, particularly achieving approximately 70% complete tumor regression in an ascites tumor model. Treatment with VV-alpha-TIGIT also significantly increases the recruitment and activation of T cells in TME.
Article
Oncology
Jiang Liu, Degan Liu, Guangyin Hu, Jingjing Wang, Dadong Chen, Chuanjun Song, Yin Cai, Chentong Zhai, Wenjing Xu
Summary: This study investigated the predictive values of circulating CD8(+) T cells and CD8(+)T/CD4(+)T cell ratio in advanced gastric cancer patients receiving immunotherapy. The results showed that patients with higher percentages of CD8(+) T and CD8(+) Tm expressing PD-1, as well as a higher PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio, had better survival outcomes. These findings provide preliminary evidence for screening the population that would benefit from immunotherapy.
CANCER CELL INTERNATIONAL
(2023)
Review
Chemistry, Multidisciplinary
Jiao-jiao Ni, Zi-zhen Zhang, Ming-jie Ge, Jing-yu Chen, Wei Zhuo
Summary: As a breakthrough strategy for cancer treatment, immunotherapy stimulates the immune system to fight cancer, providing a durable antitumor response. Due to the low response rate and unique toxicity profiles of immunotherapy, combining it with other therapies has gained attention. Immune-based combination therapy has achieved promising results in clinical trials, with FDA approval for certain cancers.
ACTA PHARMACOLOGICA SINICA
(2023)
Article
Oncology
Jacqueline E. Mann, Liliana Lucca, Matthew R. Austin, Ross D. Merkin, Marie E. Robert, Badr Al Bawardy, Khadir Raddassi, Lilach Aizenbud, Nikhil S. Joshi, David A. Hafler, Clara Abraham, Kevan C. Herold, Harriet M. Kluger
Summary: Immune checkpoint inhibitors (ICIs) are commonly used in cancer treatment, but they can cause immune-related adverse events, such as colitis. This study investigated the changes in immune environments during the progression and treatment of colitis induced by pembrolizumab. The findings suggest that specific T-cell subsets might contribute to inflammation and response to immune suppression, highlighting the importance of further exploring the colon immune environment and evaluating biologics for ICI-colitis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)